about
Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemiaActivation of KLF1 Enhances the Differentiation and Maturation of Red Blood Cells from Human Pluripotent Stem Cells.Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells.High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules.Investigation into omacetaxine solution stability for in vitro study.Lentivirus-mediated reprogramming of somatic cells in the absence of transgenic transcription factors.Human embryonic stem cells: origins, characteristics and potential for regenerative therapy.Punish the parent not the progeny.Generation of a High Number of Healthy Erythroid Cells from Gene-Edited Pyruvate Kinase Deficiency Patient-Specific Induced Pluripotent Stem Cells.Circular RNA enrichment in platelets is a signature of transcriptome degradationHigh-Efficiency Serum-Free Feeder-Free Erythroid Differentiation of Human Pluripotent Stem Cells Using Small Molecules.Prospects for the manufacture of red cells for transfusion.Red blood cells from pluripotent stem cells for use in transfusion.Identifying viable regulatory and innovation pathways for regenerative medicine: a case study of cultured red blood cells.Derivation of vascular endothelial cells from human embryonic stem cells under GMP-compliant conditions: towards clinical studies in ischaemic disease.Role of microRNAs 99b, 181a, and 181b in the differentiation of human embryonic stem cells to vascular endothelial cells.Large-scale transcriptional profiling and functional assays reveal important roles for Rho-GTPase signalling and SCL during haematopoietic differentiation of human embryonic stem cells.Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells.Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo.Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis.Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate.Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate.PET Cell Tracking Using 18F-FLT is Not Limited by Local Reuptake of Free Radiotracer.Isolation and therapeutic potential of human haemopoietic stem cells.BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta.Human mesenchymal stem cells isolated from olfactory biopsies but not bone enhance CNS myelination in vitro.All-trans retinoic acid increases transgene expression in MSCV-transduced cells, via a mechanism that is retinoid receptor dependent but independent of cellular differentiation.Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib.Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells.Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.Good Manufacturing Practice (GMP) Translation of Advanced Cellular Therapeutics: Lessons for the Manufacture of Erythrocytes as Medicinal Products.Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cellsEstrone potentiates myeloid cell differentiationGenetic programming of macrophages generates an in vitro model for the human erythroid island nicheHuman umbilical cord perivascular cells improve human pancreatic islet transplant function by increasing vascularization
P50
Q28472176-A358314D-5D7D-4EAA-BAAC-EBC363D48BF8Q33578349-76DB8A88-18CF-4A59-9E62-B482C0F18F64Q33640618-A15E59D4-A65A-417F-8222-A11B754BB765Q33696424-3BA2C88D-D93C-41F3-AE76-1AA8DE0BA9CEQ33989052-2D52AFDA-EB6E-472D-857C-3547A2533DB3Q34383023-E875F4BC-0671-48BD-BAF0-1140B6031534Q34750670-7D8A629B-B1D7-4397-9064-559BA6CB2EBBQ35940421-A239EAD7-CFA9-4B52-A01C-ED003A98A9D8Q36379316-4F2B0DFA-8F85-4843-A700-738EB626177BQ36700678-294F3B17-4A29-49AA-8A24-46EAA571C476Q37272414-53050F1C-7AAE-4D78-8023-FBF908E14EBFQ37691469-A9EB510B-15FC-4A6D-A41D-1D92647A4E40Q37747344-7FFA8A76-64B2-4EC8-9B8A-EFE455D7A1DDQ39148468-92F0A43C-58DB-43F7-88A5-F5F5B8880000Q39303886-E547D7B6-17EA-49D8-B32E-A418278ED2F6Q39414649-E85C073A-6D11-4596-B27F-1D24FB897206Q39470185-00FF74B4-D9FD-435E-BECC-5FF487624CD8Q39648017-28D6A24C-DAC7-4282-B331-C9B43C282846Q39709094-1715126A-59F1-432D-9C0C-60EC0352C6A6Q39807616-775D3C64-D418-46D3-9A5A-34D50BFEAC68Q40085449-47E64BC8-028F-45AC-A880-49C1D0BA946FQ40289723-44F3E45C-B455-4A8E-8A05-214B6055CAD6Q40363018-8BCDCDF9-4064-4294-9B56-59694CCCF252Q41785188-7629F51C-29EE-4771-9EE5-ACE53255BE63Q41787137-AFD55364-B0B0-476C-9FCD-D7F2002E1C0BQ43279503-B3D817FE-F0A3-4235-975A-AC0306657CCBQ44572415-01E9CEE5-882F-47E2-A0D4-0F561F9F2AEAQ45259481-2577BB1C-16CB-478A-99A5-4A6768333A2DQ46036650-AA71A5C1-F2E2-4AAF-8402-7D75C17DB8E9Q46187659-F466EF30-AA6E-4D90-96FB-288592C25154Q46937459-0053EF04-A66E-4D06-9F1B-33E47ED5C60AQ50094006-CA859405-13BA-415E-AC53-7CB3ECC76888Q60490274-069BE75C-07C2-4270-9422-EB44F69C95D3Q62086231-EEC8FC19-9C24-46C2-BE76-1607643A53FFQ64263340-7ECBDDAB-0D44-44AB-AA98-BB919A032A46Q92668311-072EF195-DC60-4F68-A72F-E3A2434E7425
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Joanne C Mountford
@ast
Joanne C Mountford
@en
Joanne C Mountford
@es
Joanne C Mountford
@nl
Joanne C Mountford
@sl
type
label
Joanne C Mountford
@ast
Joanne C Mountford
@en
Joanne C Mountford
@es
Joanne C Mountford
@nl
Joanne C Mountford
@sl
prefLabel
Joanne C Mountford
@ast
Joanne C Mountford
@en
Joanne C Mountford
@es
Joanne C Mountford
@nl
Joanne C Mountford
@sl
P106
P21
P31
P496
0000-0003-2142-6572
P569
2000-01-01T00:00:00Z